StockUS listing USGWINPINKHealthcareBalanced

Glorywin Entertainment Group Inc(GWIN) Stock Analysis | Healthcare

USD --+0.00%
Reward50Moderate
Risk24Low
75%Data
USD —+0.00 (+0.00%) Previous close · PINK
Market cap 54.53M
Reward Ratingⓘ50 Moderate reward assessment · 75% data coverage
Bottom 50% of stocksView factors
Risk Ratingⓘ24 Low risk assessment · 75% data coverage
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on GWIN to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Glorywin Entertainment Group Inc?

is a 3D bioprinting technology research and development, anti-cancer drug research and development.

AI Brief Pro

The brief on Glorywin Entertainment Group Inc

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Glorywin Entertainment Group Inc?

is a 3D bioprinting technology research and development, anti-cancer drug research and development. The company was incorporated in 2010 and is based in Denton, Texas. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 54.53M.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Profitability metrics are mixed — margins may be under pressure.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (50)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
BetaN/A
Insider Activity
12M windowNo data
No insider activity data available for this ticker.